Comments
Loading...
Exagen Analyst Ratings and Price Targets | NASDAQ:XGN | Benzinga
Exagen Inc has a consensus price target of $9.25 based on the ratings of 4 analysts. The high is $17 issued by Keybanc on May 13, 2022. The low is $5 issued by BTIG on March 22, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Canaccord Genuity, and Cantor Fitzgerald on January 13, 2025, January 3, 2025, and May 14, 2024, respectively. With an average price target of $7.33 between Cantor Fitzgerald, Canaccord Genuity, and Cantor Fitzgerald, there's an implied 5.59% upside for Exagen Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Canaccord Genuity
BTIG
Keybanc
1calculated from analyst ratings
Analyst Ratings for Exagen
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/13/2025 | Buy Now | 15.19% | Cantor Fitzgerald | Ross Osborn45% | $8 → $8 | Reiterates | Overweight → Overweight | Get Alert |
| 01/03/2025 | Buy Now | 0.79% | Canaccord Genuity | Kyle Mikson34% | $5 → $7 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 0.79% | Cantor Fitzgerald | Ross Osborn45% | $5 → $7 | Maintains | Overweight | Get Alert |
| 09/26/2023 | Buy Now | -13.61% | Cantor Fitzgerald | Ross Osborn45% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | -13.61% | Cantor Fitzgerald | Ross Osborn45% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 05/16/2023 | Buy Now | -13.61% | Cantor Fitzgerald | Ross Osborn45% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2023 | Buy Now | -28.01% | BTIG | Mark Massaro72% | $6 → $5 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 0.79% | BTIG | Mark Massaro72% | $10 → $7 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 0.79% | Canaccord Genuity | Kyle Mikson34% | $8 → $7 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | 144.78% | Keybanc | Paul Knight55% | $20 → $17 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Exagen (XGN) stock?
The latest price target for Exagen (NASDAQ:XGN) was reported by Cantor Fitzgerald on January 13, 2025. The analyst firm set a price target for $8.00 expecting XGN to rise to within 12 months (a possible 15.19% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exagen (XGN)?
The latest analyst rating for Exagen (NASDAQ:XGN) was provided by Cantor Fitzgerald, and Exagen reiterated their overweight rating.
When was the last upgrade for Exagen (XGN)?
There is no last upgrade for Exagen
When was the last downgrade for Exagen (XGN)?
There is no last downgrade for Exagen.
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.
Is the Analyst Rating Exagen (XGN) correct?
While ratings are subjective and will change, the latest Exagen (XGN) rating was a reiterated with a price target of $8.00 to $8.00. The current price Exagen (XGN) is trading at is $6.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
